We can identify a progression earlier and advance sooner to 2nd/3rd line treatment

We can identify patients that are more likely to have complications

We can identify complications earlier and treat them accordingly

We can use DQIBs for 'window trials' to see whether the drug affects the cancer

We can combine DQIBs (cheap and easier to implement) with molecular assays ( expensive and harder to implement)

We can make the process of drug development more efficient and cost effective

We can analyse large volumes of data in a more efficient, privacy preserving way, using DistriM

Clos Chanmurly 13
4000 Liège

©2019 by Oncoradiomics. - BE 0662.719.440